Keywords = Trastuzumab
Evaluation of Pathological Complete Response Rate in Patients with HER2-Positive Breast Cancer Undergoing Neoadjuvant Trastuzumab and Chemotherapy With or Without Anthracycline

Volume 27, Issue 1, January 2026, Pages 53-60

Iago Mateus Rocha; Alysson Bastos Lustosa; Ana Beatriz Tavares Filgueira; Giulianna Aparecida Vieira Barreto; Larissa Mont’e Alverne; Paulo Goberlanio de Barros Silva; Sergio Ferreira Juacaba


Does Trastuzumab Offer Good Value for Money for Breast Cancer Patients with Metastasis in Indonesia?

Volume 23, Issue 7, July 2022, Pages 2441-2447

Erna Kristin; Dwi Endarti; Levina Chandra Khoe; Woro Rukmi Pratiwi; Rizaldy Taslim Pinzon; Ratih Puspita Febrinasari; Alfi Yasmina; Dwi Aris Agung Nugrahaningsih; Kartika Widayati Taroeno-Hariadi; Ramadhan Karsono; I Wayan Sudarsa; Muhammad Darwin Prenggono; Eva Herlinawaty; Kalsum Komaryani; Budi Hidayat; Mardiati Nadjib


Prognostic Value of Tumor Infiltrating Lymphocytes in Locally Advanced HER2 Enriched Breast Cancer

Volume 23, Issue 2, February 2022, Pages 553-560

Mostafa M Saber; Heba M El Zawahry; Amany M Hilal; Amany A Abou-Bakr; Alfred E Namour; Mona M Saber


The Role of Human Epidermal Growth Factor Receptor (HER2/neu) in the Prognosis of Patients with Gastric Cancer

Volume 20, Issue 7, July 2019, Pages 1989-1994

Mozaffar Aznab; Davood Maleksabet; Sdigheh Khazaei; Mansour Khazaei; Mansour Rezaei


BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model

Volume 18, Issue 8, August 2017, Pages 2209-2213

Satyajit Patra; Vanesa Young; Leslie Llewellyn; Jitendra Senapati; Jesil Mathew


Outcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast Cancer

Volume 18, Issue 4, April 2017, Pages 1151-1156

Wirsma Arif Harahap; A Ramadhan; Daan Khambri; Samuel Haryono; Ricvan Dana Nindrea